Valuation: Telix Pharmaceuticals Limited

Market Cap 5.5B 3.89B 3.36B 3.14B 2.88B 5.42B 370B 36.82B 14.45B 185B 14.59B 14.27B 613B P/E 2026 *
234x
P/E 2027 * 99.8x
Enterprise Value 5.91B 4.17B 3.61B 3.37B 3.09B 5.82B 397B 39.57B 15.53B 199B 15.68B 15.33B 658B EV / Sales 2026 *
4.2x
EV / Sales 2027 * 3.68x
Free-Float
83.35%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Telix Pharmaceuticals Limited

1 day+3.27%
1 week+17.09%
Current month+17.66%
1 month+2.77%
3 months+11.84%
6 months+66.20%
Current year+49.29%
1 week 14.31
Extreme 14.31
16.78
1 month 13.95
Extreme 13.95
16.78
Current year 8.26
Extreme 8.26
17.76
1 year 8.26
Extreme 8.26
19.07
3 years 8.2
Extreme 8.2
31.97
5 years 3.55
Extreme 3.55
31.97
10 years 0.46
Extreme 0.46
31.97
Manager TitleAgeSince
Chief Executive Officer 51 03/01/2017
Director of Finance/CFO 61 31/07/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 51 03/01/2017
Chairman 66 03/02/2026
Director/Board Member 68 19/06/2018
Date Insider Type Main position Quantity % Market Cap.
11/6/25 A Fiscal year

Founder

100,708 0.0298%
6/17/25 A Free

Founder

2,595 0.0008%
6/17/25 A Free

Founder

166,483 0.0494%
Change 5-day change 1-year change 3-year change Capi.($)
+3.27%+17.09%-1.01%+65.38% 3.89B
+0.99%+1.78%+5.07%+17.01% 49.47B
+3.71%+9.40%+486.14%+592.61% 43.97B
+5.60%+10.21%+20.85%+73.63% 39.6B
+2.70%+1.57%+32.71%+9.15% 39.29B
+2.21%+6.75%+20.20%+47.53% 32.43B
+2.23%+4.71% - - 16.84B
+0.97%+2.35%+35.99%+122.50% 16.49B
-0.11%+2.41%+5.03%+20.01% 14.01B
+0.75%+15.04%+79.84%+23.95% 12.77B
Average +2.23%+7.08%+76.09%+107.98% 26.88B
Weighted average by Cap. +2.55%+6.21%+103.50%+137.25%

Financials

2026 *2027 *
Net sales 1.41B 993M 859M 802M 736M 1.38B 94.52B 9.41B 3.69B 47.38B 3.73B 3.65B 157B 1.62B 1.14B 990M 925M 848M 1.6B 109B 10.85B 4.26B 54.61B 4.3B 4.2B 181B
Net income 16.84M 11.89M 10.29M 9.61M 8.81M 16.57M 1.13B 113M 44.23M 567M 44.65M 43.68M 1.88B 41.97M 29.64M 25.64M 23.94M 21.96M 41.31M 2.82B 281M 110M 1.41B 111M 109M 4.67B
Net Debt 410M 290M 251M 234M 215M 404M 27.57B 2.75B 1.08B 13.82B 1.09B 1.06B 45.69B 469M 331M 286M 267M 245M 461M 31.51B 3.14B 1.23B 15.79B 1.24B 1.22B 52.21B
Logo Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Employees
1,152
Date Price Change Volume
10/08/26 A$16.72 +3.27% 1,439,794
07/08/26 A$16.19 +7.65% 2,630,762
06/08/26 A$15.04 +2.17% 1,304,473
05/08/26 A$14.72 +2.15% 1,157,576
04/08/26 A$14.41 +0.91% 1,239,098
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
16.19AUD
Average target price
23.48AUD
Spread / Average Target
+45.02%

Quarterly revenue - Rate of surprise